

Freedom of Information Request: Our Reference CTMUHB_269_22

You asked:

Q1. In the last 3 months, how many patients has your Health Board treated (for any condition) with the following treatments:

- **Avatrombopag**
- **Eltrombopag**
- **Fostamatinib**
- **Romiplostim**

Please find below a table populated with the data that Medicines Management are able to provide in relation to Q1. The period the data relates to is the latest 3 months available 1st May 22 to 31 July 22.

| Medicine | Number of Patients |
|-----------------|---------------------------|
| Avatrombopag | 0 |
| Eltrombopag | 11 |
| Fostamatinib | 0 |
| Romiplostim | 5 |

Q2. In the last 3 months, how many patients has your Health Board treated for Immune thrombocytopenia (ICD10 code D69.3)?

We can confirm that the Health Board does hold this information. However, to release the specific information in the way that you have requested would mean disclosure of low numbers.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain.

In our view disclosure of these low figures would breach the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

However, in order to fulfil our obligation under Section 16 of the Act to provide advice and assistance, for the date range 01.01.22 - 31.03.22 we can confirm that there have been less than 5 inpatient episodes for Immune thrombocytopenia (ICD10 code D69.3).

Q3. In the last 3 months, how many patients has your Health Board treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:

- **Avatrombopag**
- **Mycophenolate mofetil**
- **Rituximab**

- **Surgery (splenectomy)**

The Health Board will not provide specific treatment details for Immune thrombocytopenia patients due to the small numbers involved (see response to Q2). It considers there is the potential for the individuals to be identified from the information provided when considered with other information that may also be in the public domain. Therefore, the Health Board has relied upon section 40(2) of the Act in respect of this request.

Q4. Does your Health Board participate in any clinical trials for the treatment of Immune thrombocytopenia? If so, can you please provide the name of each trial and the number of patients taking part.

We can confirm that the Health Board are not currently participating in any clinical trials for the treatment of Immune thrombocytopenia.